David Shaw’s Inhibrx INBX Stock Holding History

David Shaw’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.67M	Hold	17,600	–	–	﹤0.01%	3356
2026 Q1	$1.18M	Hold	17,600	–	–	﹤0.01%	3322
2025 Q4	$1.39M	Buy	+17,600	New	+$1.2M	﹤0.01%	3323

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

David Shaw's INBX Position: Q2 2026 in Review

David Shaw reduced its Inhibrx (INBX) stake by 71% in Q2 2026, selling an estimated $5.52M and leaving 22,322 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3151.

David Shaw first reported a position in INBX in Q3 2025 and has held it in 4 quarters since. The position peaked at $9.65M in Q4 2025. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

David Shaw held 22,322 shares of Inhibrx worth $2.12M as of Q2 2026.
David Shaw sold 55,115 Inhibrx shares in Q2 2026, an estimated $5.52M.
Inhibrx made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3151 holding.
David Shaw first reported a position in Inhibrx in Q3 2025 and has held it in 4 quarters since.
David Shaw's Inhibrx position peaked at $9.65M in Q4 2025.
163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.